May 31, 2020
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Apr 01, 2020
FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
Mar 12, 2020
Induced Pluripotent Stem Cells Show Success in Treating Hemophilia A in Mice
Jan 02, 2020
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Dec 23, 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Dec 06, 2019
Results from the PROTECT VIII Extension Study with Jivi® Published in Haemophilia
Nov 21, 2019
BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Jul 19, 2019
Bayer statement on voluntary recall of two lots of Kogenate® FS antihemophilic factor (recombinant) in the United States
Jun 26, 2019
Bayer to present new data from its hemophilia A portfolio at the International Society of Thrombosis and Haemostasis (ISTH) 2019 annual congress
Jun 18, 2019
Health Canada Approves Hemlibra® for Hemophilia A Patients Without Factor VIII Inhibitors
May 28, 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
May 28, 2019
BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Dec 04, 2018
Bayer Presents Five-Year Outcomes Data from the PROTECT VIII Extension Study at the 60th American Society of Hematology Annual Meeting
Aug 30, 2018
Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen
Jul 09, 2018
BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive
May 22, 2018
BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress
May 21, 2018
Sobi Emphasises Commitment to Haemophilia Community at WFH 2018 World Congress
May 17, 2018
BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress
Apr 20, 2018
Prime Therapeutics Finds Costs Double When Switching to New Extended Half-Life Hemophilia Factor Products
Apr 11, 2018
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada